Recently, our R&D team has successfully completed a new round of technological optimization and formulation improvement based on our existing veterinary antibacterial products. The upgrade focuses on enhancing product stability and bioavailability under complex farming environments, while further improving the prevention and control effects against common bacterial diseases.
The upgrade was carried out in several key areas:
First, in terms of raw material selection, the company has adopted higher-purity pharmaceutical-grade active ingredients. Through a multi-layer quality inspection system, every batch of raw materials strictly meets international quality standards, ensuring product safety and consistency from the source.
Second, in formulation technology, improved micronization and sustained-release technologies have been applied to achieve more uniform drug absorption in animals. This extends the effective duration of action, improves therapeutic efficiency, reduces dosing frequency, and helps lower overall breeding costs.
In addition, the new formulation has been optimized for palatability and tolerance, making it suitable for a wide range of livestock including pigs, cattle, sheep, and poultry. It has demonstrated excellent safety and stability in practical applications.
The company’s technical director stated that this upgrade is not only an improvement in product performance but also an important step in implementing the company’s philosophy of “scientific medication and green farming.” Going forward, the company will continue to increase investment in animal health R&D and promote the development of veterinary products toward higher efficiency, safety, and environmental sustainability.
Currently, the upgraded product has entered mass production and is gradually being introduced to the market, receiving positive feedback from livestock customers in multiple regions.